Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction - PubMed (original) (raw)
. 2007 Nov;8(11):1246-54.
doi: 10.1038/ni1515. Epub 2007 Sep 30.
Daniel G Kavanagh, Florencia Pereyra, John J Zaunders, Elizabeth W Mackey, Toshiyuki Miura, Sarah Palmer, Mark Brockman, Almas Rathod, Alicja Piechocka-Trocha, Brett Baker, Baogong Zhu, Sylvie Le Gall, Michael T Waring, Ryan Ahern, Kristin Moss, Anthony D Kelleher, John M Coffin, Gordon J Freeman, Eric S Rosenberg, Bruce D Walker
Affiliations
- PMID: 17906628
- DOI: 10.1038/ni1515
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
Daniel E Kaufmann et al. Nat Immunol. 2007 Nov.
Abstract
In progressive viral infection, antiviral T cell function is impaired by poorly understood mechanisms. Here we report that the inhibitory immunoregulatory receptor CTLA-4 was selectively upregulated in human immunodeficiency virus (HIV)-specific CD4(+) T cells but not CD8(+) T cells in all categories of HIV-infected subjects evaluated, with the exception of rare people able to control viremia in the absence of antiretroviral therapy. CTLA-4 expression correlated positively with disease progression and negatively with the capacity of CD4(+) T cells to produce interleukin 2 in response to viral antigen. Most HIV-specific CD4(+) T cells coexpressed CTLA-4 and another inhibitory immunoregulatory receptor, PD-1. In vitro blockade of CTLA-4 augmented HIV-specific CD4(+) T cell function. These data, indicating a reversible immunoregulatory pathway selectively associated with CD4(+) T cell dysfunction, provide a potential target for immunotherapy in HIV-infected patients.
Similar articles
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. Day CL, et al. Nature. 2006 Sep 21;443(7109):350-4. doi: 10.1038/nature05115. Epub 2006 Aug 20. Nature. 2006. PMID: 16921384 - Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction.
D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, Wilson CC, Connick E, Palmer BE. D'Souza M, et al. J Immunol. 2007 Aug 1;179(3):1979-87. doi: 10.4049/jimmunol.179.3.1979. J Immunol. 2007. PMID: 17641065 - CD4+ and CD8+ T cells expressing FoxP3 in HIV-infected patients are phenotypically distinct and influenced by disease severity and antiretroviral therapy.
Lim A, French MA, Price P. Lim A, et al. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):248-57. doi: 10.1097/QAI.0b013e3181a74fad. J Acquir Immune Defic Syndr. 2009. PMID: 19363449 - The inhibitory co-receptors: a way to save from anergy the HIV-specific T cells.
Simone R, Piatti G, Saverino D. Simone R, et al. Curr HIV Res. 2009 May;7(3):266-72. doi: 10.2174/157016209788347949. Curr HIV Res. 2009. PMID: 19442121 Review. - Revisiting immune exhaustion during HIV infection.
Khaitan A, Unutmaz D. Khaitan A, et al. Curr HIV/AIDS Rep. 2011 Mar;8(1):4-11. doi: 10.1007/s11904-010-0066-0. Curr HIV/AIDS Rep. 2011. PMID: 21188556 Free PMC article. Review.
Cited by
- Artificial antigen-presenting cell system reveals CD28's role in modulating T cell functions during human immunodeficiency virus infection.
Kabakibo TS, Arnold E, Padhan K, Lemieux A, Ortega-Delgado GG, Routy JP, Shoukry N, Dubé M, Kaufmann DE. Kabakibo TS, et al. iScience. 2024 Sep 13;27(10):110947. doi: 10.1016/j.isci.2024.110947. eCollection 2024 Oct 18. iScience. 2024. PMID: 39381752 Free PMC article. - Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
Webb GM, Pessoa CT, McCullen AJ, Hwang JM, Humkey MC, Thormin-Odum R, Kukula KA, Smedley J, Fischer M, Sciurba J, Bochart RM, Shriver-Munsch C, Ndhlovu LC, Sacha JB. Webb GM, et al. J Virol. 2024 Jun 13;98(6):e0027324. doi: 10.1128/jvi.00273-24. Epub 2024 May 22. J Virol. 2024. PMID: 38775481 - SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals.
Urschel R, Bronder S, Klemis V, Marx S, Hielscher F, Abu-Omar A, Guckelmus C, Schneitler S, Baum C, Becker SL, Gärtner BC, Sester U, Martinez L, Widera M, Schmidt T, Sester M. Urschel R, et al. Nat Commun. 2024 Apr 9;15(1):3077. doi: 10.1038/s41467-024-47429-8. Nat Commun. 2024. PMID: 38594497 Free PMC article. - Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
Gay CL, Bosch RJ, McKhann A, Cha R, Morse GD, Wimbish CL, Campbell DM, Moseley KF, Hendrickx S, Messer M, Benson CA, Overton ET, Paccaly A, Jankovic V, Miller E, Tressler R, Li JZ, Kuritzkes DR, Macatangay BJC, Eron JJ, Hardy WD; A5370 Team. Gay CL, et al. Open Forum Infect Dis. 2024 Jan 11;11(3):ofad694. doi: 10.1093/ofid/ofad694. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38449916 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials